Antibody-based inhibition of the CD70/CD27 interaction in combination with TKIs significantly targeted the CD34+ CML stem/progenitor cells in vitro and in vivo. Here, CD27 is linked to chronic myelogenous leukemia, BCR-ABL1 positive.